clinical improvement psoriasis specific targeting interleukin- 
psoriasis chronic inflammatory skin disorder affects approximately % population worldwide severe effects patients physical psychological well-being- discovery psoriasis immune-mediated disease led targeted effective therapies recent advances focused interleukin il-/23p40 subunit shared il il- evidence suggests specific inhibition il result improvement psoriasis evaluate tildrakizumab monoclonal antibody targets il-23p19 subunit three-part randomized placebo-controlled sequential rising multiple-dose phase study patients moderate-to-severe psoriasis provide clinical proof specific targeting il-23p19 results symptomatic improvement disease severity human subjects % reduction psoriasis area severity index pasi score pasi75 achieved subjects parts pooled mg kg- groups day part subjects mg kg- group subjects mg kg- group achieved pasi75 day tildrakizumab demonstrated important clinical improvement moderate-to-severe psoriasis patients demonstrated improvements pasi scores histological samples 
